Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Araujo AM, et al. Among authors: jenkins l. J Clin Invest. 2022 Oct 3;132(19):e165107. doi: 10.1172/JCI165107. J Clin Invest. 2022. PMID: 36169029 Free PMC article. No abstract available.
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Araujo AM, et al. Among authors: jenkins l. J Clin Invest. 2022 Apr 1;132(7):e148667. doi: 10.1172/JCI148667. J Clin Invest. 2022. PMID: 35192545 Free PMC article.
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR. Wagner S, et al. Among authors: jenkins l. Oncogene. 2019 Mar;38(10):1717-1733. doi: 10.1038/s41388-018-0554-z. Epub 2018 Oct 23. Oncogene. 2019. PMID: 30353166 Free PMC article.
Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR. Wagner S, et al. Among authors: jenkins l. Oncogene. 2019 Jul;38(28):5746. doi: 10.1038/s41388-019-0835-1. Oncogene. 2019. PMID: 31147600 Free PMC article.
Covalent Modification of p53 by (E)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.
Brown K, Robello M, Perciaccante AJ, Dinan JC, Maity TK, Lyons GC, Kumar JP, Durell SR, Tagad HD, Schilling D, Nikolayevskiy H, O'Connor R, Appella E, Appella DH, Jenkins LM. Brown K, et al. Among authors: jenkins lm. ACS Pharmacol Transl Sci. 2024 Oct 14;7(11):3559-3572. doi: 10.1021/acsptsci.4c00447. eCollection 2024 Nov 8. ACS Pharmacol Transl Sci. 2024. PMID: 39539265
1,113 results